| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1106 | 2016 |
| Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for … Z Piotrowska, H Isozaki, JK Lennerz, JF Gainor, IT Lennes, VW Zhu, ... Cancer discovery 8 (12), 1529-1539, 2018 | 384 | 2018 |
| Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer JJ Lin, VW Zhu, S Yoda, BY Yeap, AB Schrock, I Dagogo-Jack, NA Jessop, ... Journal of Clinical Oncology 36 (12), 1199, 2018 | 300 | 2018 |
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... Cancer discovery 8 (6), 714-729, 2018 | 271 | 2018 |
| Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer JF Gainor, D Tseng, S Yoda, I Dagogo-Jack, L Friboulet, JJ Lin, ... JCO precision oncology 1, 1-13, 2017 | 268 | 2017 |
| Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC H Terai, K Soejima, H Yasuda, S Nakayama, J Hamamoto, D Arai, ... Molecular cancer research 11 (7), 759-767, 2013 | 220 | 2013 |
| RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies BJ Solomon, L Tan, JJ Lin, SQ Wong, S Hollizeck, K Ebata, BB Tuch, ... Journal of Thoracic Oncology 15 (4), 541-549, 2020 | 219 | 2020 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 185 | 2018 |
| Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer JJ Lin, SV Liu, CE McCoach, VW Zhu, AC Tan, S Yoda, J Peterson, A Do, ... Annals of Oncology 31 (12), 1725-1733, 2020 | 166 | 2020 |
| Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells H Watanabe, K Soejima, H Yasuda, I Kawada, I Nakachi, S Yoda, K Naoki, ... Cancer cell international 8, 1-12, 2008 | 158 | 2008 |
| MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer I Dagogo-Jack, S Yoda, JK Lennerz, A Langenbucher, JJ Lin, MM Rooney, ... Clinical Cancer Research 26 (11), 2535-2545, 2020 | 146 | 2020 |
| Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA I Dagogo-Jack, AR Brannon, LA Ferris, CD Campbell, JJ Lin, KR Schultz, ... JCO precision oncology 2, 1-14, 2018 | 131 | 2018 |
| The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models R Katayama, BO Gong, N Togashi, M Miyamoto, M Kiga, S Iwasaki, ... Nature Communications 10 (1), 3604, 2019 | 119 | 2019 |
| Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma J Hamamoto, K Soejima, S Yoda, K Naoki, S Nakayama, R Satomi, ... Molecular medicine reports 8 (2), 456-462, 2013 | 86 | 2013 |
| Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer JJ Lin, NJ Choudhury, S Yoda, VW Zhu, TW Johnson, R Sakhtemani, ... Clinical Cancer Research 27 (10), 2899-2909, 2021 | 79 | 2021 |
| Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities S Yoda, I Dagogo-Jack, AN Hata Pharmacology & therapeutics 193, 20-30, 2019 | 65 | 2019 |
| FOXD1 expression is associated with poor prognosis in non-small cell lung cancer S Nakayama, K Soejima, H Yasuda, S Yoda, R Satomi, S Ikemura, ... Anticancer research 35 (1), 261-268, 2015 | 59 | 2015 |
| Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer K Ohgino, K Soejima, H Yasuda, Y Hayashi, J Hamamoto, K Naoki, D Arai, ... Lung Cancer 83 (1), 90-96, 2014 | 56 | 2014 |
| The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct … K Naoki, K Soejima, H Okamoto, J Hamamoto, N Hida, I Nakachi, ... International journal of clinical oncology 16, 335-344, 2011 | 56 | 2011 |
| Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer S Yoda, K Soejima, J Hamamoto, H Yasuda, S Nakayama, R Satomi, ... Lung cancer 85 (3), 366-372, 2014 | 51 | 2014 |
